European Journal of Cancer
Volume 37, Issue 18 , Pages 2470-2474 , December 2001

Screening of selected genomic areas potentially involved in thyroid neoplasms

  • J Oriola

      Affiliations

    • Servei d́Hormonologia, Hospital Clı́nic i Universitari, IDIBAPS, Barcelona, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34-3-227-5400 x2667; fax: +34-3-227-5454
    • ,
  • I Halperin

      Affiliations

    • Servei d́Endocrinologia, Hospital Clı́nic i Universitari, IDIBAPS, Barcelona, Spain
    • ,
  • C Mallofré

      Affiliations

    • Servei d́Anatomia Patològica, Hospital Clı́nic i Universitari, IDIBAPS, Barcelona, Spain
    • ,
  • J Muntané

      Affiliations

    • Servei d́Anatomia Patològica, Hospital Clı́nic i Universitari, IDIBAPS, Barcelona, Spain
    • ,
  • M Angel

      Affiliations

    • Servei d́Endocrinologia, Hospital Clı́nic i Universitari, IDIBAPS, Barcelona, Spain
    • ,
  • F Rivera-Fillat

      Affiliations

    • Servei d́Hormonologia, Hospital Clı́nic i Universitari, IDIBAPS, Barcelona, Spain

Received 9 April 2001 ,Revised 26 June 2001 ,Accepted 30 August 2001.

References 

  1. Namba H, Matsuo K, Fagin JA. Clonal composition of benign and malignant human thyroid tumors. J. Clin. Invest. 1990;86:120–125
  2. Krohn K, Fuhrer D, Holzapfel HP, Paschke R. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J. Clin. Endocrinol. Metab. 1998;83:130–134
  3. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol. Endocrinol. 1990;15:1162–1168
  4. Fenton C, Anderson J, Lukes Y, Dinauer CA, Tuttle RM, Francis GL. Ras mutations are uncommon in sporadic thyroid cancer in children and young adults. J. Endocrinol. Invest. 1999;22:781–789
  5. Suarez HG, du Villard JA, Caillou B, Schlumberger M, Parmentier C, Monier R. Gsp mutations in human thyroid tumours. Oncogene. 1991;6:677–679
  6. Parma J, Duprez L, Van Sande J, et al.  Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature. 1993;365:649–651
  7. Grieco M, Santoro M, Berlingieri MT, et al.  PTC is a novel rearranged form of the ret protooncogene and is frequently detected in vivo in human papillary carcinomas. Cell. 1990;60:557–563
  8. Bounacer A, Wicker R, Schlumberger M, Sarasin A, Suarez HG. Oncogenic rearrangements of the ret proto-oncogene in thyroid tumors induced after exposure to ionizing radiation. Biochimie. 1997;79:619–623
  9. Park KY, Koh JM, Kim YI, et al.  Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin. Endocrinol. 1998;49:317–323
  10. Ito T, Seyama T, Mizuno T, et al.  Unique association of P53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992;52:1369–1371
  11. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffer HP. High prevalence of mutations of the P53 gene in poorly differentiated human thyroid carcinoma. J. Clin. Invest. 1993;91:179–184
  12. Grebe SK, McIver B, Hay ID, et al.  Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J. Clin. Endocrinol. Metab. 1997;82:3684–3691
  13. Dahiya R, McCarville J, Hu W, et al.  Chromosome 3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma. Int. J. Cancer. 1997;71:20–25
  14. Kroll TG, Sarraf P, Pecciarini L, et al.  PAX8-PPARγ1 fusion in oncogene human thyroid carcinoma. Science. 2000;289:1357–1360
  15. Zhang JS, Nelson M, McIver B, et al.  Differential loss of heterozygosity at 7q31.2 in follicular and papillary thyroid tumors. Oncogene. 1998;17:789–793
  16. Trovato M, Fraggetta F, Villari D, et al.  Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 1999;84:3235–3240
  17. Nagase S, Sato S, Tezuka F, Wada Y, Yajima A, Horii A. Deletion mapping on chromosome 10q25–q26 in human endometrial cancer. Br. J. Cancer. 1996;74:1979–1983
  18. Zedenius J, Wallin G, Svensson A, et al.  Allelotyping of follicular thyroid tumors. Hum. Genet. 1995;96:27–32
  19. Zedenius J, Wallin G, Svensson A, et al.  Deletions of the long arm of chromosome 10 in progression of follicular thyroid tumors. Hum. Genet. 1996;97:299–303
  20. Dahia PL, Marsh DJ, Zheng Z, et al.  Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997;57:4710–4713
  21. Califano JA, Johns III MM, Westra WH, et al.  An allelotype of papillary thyroid cancer. Int. J. Cancer. 1996;69:442–444
  22. Fagin JA. Molecular defects in thyroid gland neoplasia. J. Clin. Endocrinol. Metab. 1992;75:1398–1400
  23. Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocr. Rev. 1994;15:202–232
  24. Wynford-Thomas D. Origin and progression of thyroid epithelial tumours (cellular and molecular mechanisms). Horm. Res. 1997;47:145–157
  25. Nayar R, Zhuang Z, Merino MJ, Silverberg SG. Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction. Hum. Pathol. 1997;28:277–282
  26. Monaco C, Negrini M, Sozzi G, et al.  Molecular cloning and characterization of LOH11CR2A, a new gene within a refined minimal region of LOH at 11q23. Genomics. 1997;46:217–222
  27. Steichen-Gersdorf E, Baumgartner M, Kreczy A, Maier H, Fink FM. Deletion mapping on chromosome 17p in medulloblastoma. Br. J. Cancer. 1997;76:1284–1287
  28. Fujii H, Biel MA, Zhou WB, Weitzman SA, Baylin SB, Gabrielson E. Methylation of the HIC-1 candidate tumor supressor gene in human breast cancer. Oncogene. 1998;16:2159–2164

PII: S0959-8049(01)00302-1

doi: 10.1016/S0959-8049(01)00302-1

European Journal of Cancer
Volume 37, Issue 18 , Pages 2470-2474 , December 2001

Article Tools

* Image Usage & Resolution